Innovative multiplex immunoassays and AI for comprehensive early detection and monitoring of high-risk individuals with pancreatic cancer
SHIELD is developing a simple, affordable blood test to detect pancreatic cancer at its earliest, most treatable stage. By identifying and testing people with elevated genetic risk, SHIELD aims to reduce late-stage diagnoses and increase Europe’s five-year survival rate from under 10% today to 30% by 2035.
A cost-effective blood test for fast, affordable, and accurate diagnosis
Shield is an Horizon Europe project uniting 27 partners across Europe.
Early detection of pancreatic cancer is crucial but challenging. While various imaging techniques and specific indicators found in blood can help spot potential issues, they aren’t always sensitive enough to find the cancer in its very earliest stages. Population-wide screening isn’t recommended due to low cancer incidence and high false positives. Instead, surveillance should focus on high-risk individuals with genetic predispositions to improve early detection and outcomes.
Project SHIELD is transforming the early detection and monitoring of pancreatic cancer. We combine cutting-edge multiplex immunoassays with artificial intelligence to identify high-risk individuals with greater accuracy and speed.
